D.E. Shaw & Co
OREX

D.E. Shaw & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

D.E. Shaw & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,229
Closed -$38K – 4115
2015
Q4 		$38K Sell
2,229
-7,545
-77% -$180K ﹤0.01% 3728
2015
Q3 		$206K Sell
9,774
-14,191
-59% -$486K ﹤0.01% 3489
2015
Q2 		$1.19M Sell
23,965
-58,291
-71% -$3.48M ﹤0.01% 2570
2015
Q1 		$6.44M Buy
82,256
+8,574
+12% +$532K 0.01% 1221
2014
Q4 		$4.46M Sell
73,682
-28,054
-28% -$1.41M 0.01% 1662
2014
Q3 		$4.33M Buy
101,736
+16,505
+19% +$886K 0.01% 1668
2014
Q2 		$5.27M Buy
85,231
+13,122
+18% +$763K 0.01% 1581
2014
Q1 		$4.69M Sell
72,109
-82,709
-53% -$5.59M 0.01% 1647
2013
Q4 		$8.72M Buy
154,818
+14,927
+11% +$839K 0.01% 1249
2013
Q3 		$8.59M Buy
139,891
+463
+0.3% +$31.4K 0.01% 1142
2013
Q2 		$8.16M Buy
+139,428
New +$8.58M 0.02% 1004

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co's OREX Position: Q1 2016 in Review

D.E. Shaw & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 2,229 shares — an estimated $38K sold.

D.E. Shaw & Co first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $8.72M in Q4 2013. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • D.E. Shaw & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,229 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $38K.
  • D.E. Shaw & Co first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • D.E. Shaw & Co's Orexigen Therapeutics, Inc. position peaked at $8.72M in Q4 2013.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.